



## **Aurobindo Pharma receives final approval for Stavudine Capsules and Oral Solution**

Aurobindo Pharma Limited is pleased to announce that two of its tentatively approved ANDAs namely Stavudine Capsules 15mg, 20mg, 30mg and 40mg and Stavudine for oral solution 1mg/mL have received the final approval from the US Food & Drug Administration (USFDA).

Stavudine Capsules 15mg, 20mg, 30mg and 40mg and Stavudine for oral solution 1mg/mL are the generic equivalent of Bristol-Myers Squibb Company's Zerit® 15mg, 20mg, 30mg and 40mg and Zerit® for oral solution 1mg/mL respectively. These fall under the Anti-Retroviral (ARV) segment and are indicated for treatment of HIV-1 infection in combination with other antiretroviral agents and has a market size of approximately US\$ 61 million for the twelve months ending June 2008 according to Newport.

Aurobindo now has 63 Final and 24 Tentative ANDA approvals from USFDA

### **About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

### **For further information, please contact:**

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad

Phone: 040-66725000 / 66725401

Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)